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Brief Communication
Investment Cost for Microalbumin Screening Compared to 
Hemoglobin A1C Screening: A Situation From a Rural 
Province in a Developing Country
Viroj Wiwanitkit
Background: Laboratory investigation for following up diabetes mellitus is recommended. Hemoglobin A1C 
and microalbumin are the two most widely used screening tests. An important concern in developing countries 
at present is the cost of a screening program.
Methods: A basic study on the funds for hemoglobin A1C and microalbumin screening in primary hospitals in 
a rural province in the developing country of Thailand was done.
Results: It was found that the fund for microalbumin in this setting is about one-fourth that for hemoglobin A1C.
Conclusion: Due to the inequality in funding allocation, there is a need for increased awareness of the importance 
of microalbumin screening for patients with diabetes mellitus. [Hong Kong J Nephrol 2010;12(2):99–101]
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INTRODUCTION
Laboratory investigation for following up diabetes 
mellitus is recommended. Hemoglobin (Hb) A1C and 
microalbumin are the two most widely used screening 
tests [1]. These two tests are recommended in all dia-
betes clinics at present [1]; HbA1C for monitoring 
glycemic control in patients [2], and microalbumin for 
the detection of early renal disorders [3]. An important 
concern in developing countries is the cost of a screen-
ing program. A basic study on the funds for HbA1C 
and microalbumin screening in primary hospitals in a 
rural province in the developing country of Thailand 
was done.
METHODS
The funds allocated to a group of 21 primary hospitals 
in a rural province in Northeast Thailand, about 650 km 
from Bangkok, the capital of Thailand, were assessed 
(the names of the hospitals are omitted due to privacy 
issues). All the primary hospitals have the same facilities 
for laboratory analyzers and other infrastructure and 
obtain their funding from the same source, the local 
public health administrator of the province. Teams from 
the provincial public health administrator office and the 
heads of the primary hospitals decide on the allocation 
of funds to the different hospitals and for which tests. 
Data on funds for HbA1C and microalbumin screening 
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Table. Funds allocated for hemoglobin A1C and microalbumin 
screening
Primary hospital
 Funding (US$)*
 Hemoglobin A1C Microalbumin
1 4,975.50 1,203.80
2 8,695.30 2,103.70
3 1,805.80 435.60
4 8,216.70 1,993.10
5 4,994.50 1,208.30
6 6,776.20 1,639.40
7 5,449.40 1,318.40
8 1,895.40 458.6
9 3,009.00 642.3
10 2,985.30 722.3
11 6,468.20 1,564.90
12 9,477.10 2,292.90
13 2,017.60 488.1
14 3,089.50 747.5
15 1,189.40 287.8
16 2,250.80 544.6
17 8,278.30 2,002.80
18 1,644.30 397.80
19 3,786.10 916.00
20 3,198.50 773.80
21 4,572.70 1,106.30
*US$1 is equivalent to 35 Thai baht.
were collected from the report that is submitted to the 
provincial center by each primary hospital, which is a 
reliable and objective source. The data were collected in 
the budget year of 2009 and the funds were intended 
for the budget year of 2010. The sum and average funds 
were calculated and presented.
RESULTS
The funds for the two laboratory tests for each primary 
hospital are shown in the Table. The total funds available 
for both tests, for the HbA1C test and the microalbumin 
test for all 21 primary hospitals were US$117,698.70, 
US$94,770.4 and US$22,928.3, respectively. The mean 
amount of funds for each hospital for both tests, for the 
HbA1C test and the microalbumin test were US$5,604.70, 
US$4,512.90 and US$1,091.80, respectively.
DISCUSSION
In a good diabetes management program, laboratory 
screening tests are needed. HbA1C screening for detec-
tion of poor glycemic control and microalbumin screen-
ing for detection of reversible nephrological disorders 
are recommended [1]. With limited resources in devel-
oping countries, the allocation of funds for medical 
diagnostic facilities has to focus on the investment cost 
[4]. There are some reports on investment costs for dia-
betes laboratories, but the reports are usually from de-
veloped countries and are on regular blood glucose 
testing [5,6]. For diabetes, as a chronic disease, the study 
of funding for biomarkers is useful for further planning 
of facilities allocation [7]. The current study shows an 
example of fund allocation in a rural province of a devel-
oping country. It was found that funds for necessary bio-
marker tests for diabetes clinics were not well distributed. 
Microalbumin screening was funded much less com-
pared to HbA1C screening.
The amount of funding for each primary hospital was 
different, and might be due to differences in the diabetes 
caseloads of each hospital. However, the interesting 
finding of this study was the much lower funding provided 
for microalbumin screening, which was about four times 
less than that for HbA1C screening. After adjusting by 
the price of the test (the microalbumin test is about two 
times cheaper than the HbA1C test), the ratio of funding 
discrepancy is still about 1:2. There is no doubt that 
HbA1C screening is useful and should be funded [8]. 
However, this does not imply that microalbumin screening 
is of less importance for determining renal impairment. 
There is no reason for why screening for early renal 
disorders should receive less funding than screening for 
poor glycemic control. Microalbumin screening can 
detect actual complications while HbA1C detects risk. 
The microalbumin test is reported to be an oft neglected 
test that receives little funding; an integrated diabetes 
management program would increase the rate of using 
this valuable clinical test [9]. The fact that microalbumin 
screening is being neglected may be due to under-
recognition of its value by both the physician (who 
would then not routinely order the test in clinical practice) 
and the funding allocator (who would then not provide 
sufficient funding). On the other hand, it is not surprising 
to see more funding for HbA1C screening because dia-
betes monitoring might be more important than detection 
of early diabetic nephropathy. Prevention is usually more 
important and effective than control of renal involvement.
What many readers would like to know is whether or 
not there was enough funding for all the necessary tests. 
Based on the principle of equal distribution of health 
care facilities to the population in the province, it is 
assumed that the number of diabetes cases in each of 
the 21 hospitals are similar (since the number of the 
population to be serviced is equally shared within the 
province and the nature of the lifestyle and demographic 
characteristics of the people to be served are similar). 
This study showed a variation in funding, which may 
reflect the poor distribution of funds made by the al-
locator. In some hospitals, there is probably not enough 
money allocated for HbA1C screening for the local 
diabetic population, although it is still more than that for 
microalbumin screening.
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In conclusion, due to the current inequality in funding 
allocation, there is a need for increased awareness of 
the importance of microalbumin screening for diabetes 
patients.
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